Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Instagram Outage Disrupts Thousands of U.S. Users 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Lunit, a deep learning-based medical AI company based in South Korea, moved closer to acquiring Volpara Health Technologies Ltd. after the high court in New Zealand issued first-phase approval for the deal.
Lunit is trying to buy Volpara Health, which specializes in making software to save people from cancer. To fulfill its mission of conquering the deadly disease through modern technology, Lunit needs to secure approval from regulators in NZ since the latter is headquartered in the region.
Moving Forward With the Buyout Deal
According to The Korea Economic Daily, the Lunit and Volpara Health agreement is finally moving forward after the high court gave its "go-ahead" for the deal to proceed. With how things are progressing, it was reported that the companies may finalize their acquisition contract by May.
On Thursday, May 14, the South Korean medical AI firm announced it had secured the first approval from the High Court of New Zealand for its plan to buy the NZ-based AI breast cancer diagnostics solutions company.
Moreover, Lunit shared that the acquisition process required by the local court in the region consists of key steps. The first is obtaining the shareholders' approval and the sale vote, and the second is assessing the validity and effectiveness of the meeting's outcome. It was noted that Volpara scheduled a shareholders' meeting for April 12.
Lunit in the American Market
Meanwhile, Lunit's acquisition of Volpara will position the company as a dominant force in the U.S. market for mammography solutions. Once merged, the companies will also improve related artificial intelligence solutions while laying out the foundation for the development of autonomous AI models in the future.
"We are pleased to announce the High Court's approval, a significant step in our remarkable journey. As we approach the final stage where Volpara's shareholders will cast their votes, I would also like to share that our funding for this acquisition is progressing seamlessly, ensuring everything is on track," Lunit's chief executive officer, Brandon Suh, said in a press release. "We are confident that the synergies between Lunit and Volpara will create a powerful force in advancing AI-driven solutions for the benefit of cancer care professionals and patients worldwide."
Photo by: Lunit Press Release
